Anixa Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANIX Nasdaq 2836 www.anixa.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anixa Biosciences, Inc.

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - Jun 1st, 2026 7:00 am
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - May 11th, 2026 9:48 am
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - May 1st, 2026 7:15 am
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - Apr 29th, 2026 7:10 am
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - Apr 22nd, 2026 6:45 am
Replays from RedChip's Biotech Investor Conference Now Available - Apr 20th, 2026 9:00 am
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Apr 14th, 2026 8:02 pm
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation - Apr 10th, 2026 10:55 am
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Apr 9th, 2026 7:05 am
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 - Apr 7th, 2026 6:55 am
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs - Apr 6th, 2026 7:10 am
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Apr 1st, 2026 6:50 am
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - Mar 30th, 2026 7:05 am
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress - Mar 13th, 2026 2:45 pm
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast - Mar 12th, 2026 8:38 am
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology - Mar 9th, 2026 6:30 am
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - Mar 2nd, 2026 7:10 am
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Feb 23rd, 2026 6:55 am
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance - Feb 10th, 2026 1:50 pm
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation - Feb 9th, 2026 6:00 am